Revolutionizing regenerative medicine
Cellergy is producing a large quantity of mitochondrial product from human primary sources for systemic, repeated administration, using fully matched allogeneic purified mitochondria delivered via IV for major systemic indications such as CNS disorders, muscle degeneration, and aging.
PROPRIETARY SOURCE AND PROCESS
Mitochondria source is the key to making effective therapy.
Our source is:
-
Primary: non-transformed primary cells.
-
High-quality: excellent respiration capacity.
-
Scalable: massive expansion of the source cells in a cost-efficient process.
MANUFACTURING
Large scale mitochondria manufacturing process, GMP-grade, to enable systemic repeated administration for multiple indications.
ALLOGENEIC
Transplantation of mitochondria from a young and healthy donor to an aging or degenerative recipient, requires careful matching.
Our breakthrough ML based model predicts donor/recipient matching, making allogeneic mitochondrial transplantation safe and effective.
Our Vision
Transforming Human Health
By providing the power of young and healthy mitochondria to energize cells, fight degenerative diseases and enhance healthy longevity.
Why Mitochondria
The Cell's Powerhouse
Mitochondria transforms food fuel into cellular energy (ATP) which is critical to all cellular functions such as protein synthesis, DNA repair, muscle contraction, and waste removal.
A single human cell contains ~500-2500 mitochondria, depending on cell type. It is most abundant in tissues with high energy demand - muscles, brain and liver.
​
Degenerative diseases, and aging, often start with damage to mitochondria. Mutations in the mtDNA accumulate, the membrane lipids get oxidized. Once energy production is depleted, the cell starts to degenerate.
Mitochondrial DNA
Mitochondria have their own small circular DNA coding for 13 proteins of the respiratory machinery; the rest of the mitochondrial proteins are encoded in the cell nucleus (~1200).
Cellergy's mitochondria IV therapy
can address multiple diseases
-
Mitochondrial Disease
-
Muscular Dystrophy
-
Multiple Sclerosis
-
Cardiomyopathy
-
Chronic Fatigue
-
Cerebral Palsy
-
Fibromyalgia
-
Huntington's
-
Parkinson's
-
Alzheimer's
-
Autism
-
Cancer
-
Epilepsy
-
Diabetes
-
Obesity
-
ALS
-
Aging
Get News & Updates
Join our email list and get industry news & updates.
Leadership Team
Rachel Diamant, MSc Eng.
Co-founder and CEO
-
20 years experience as an entrepreneur in biotech.
-
Co-founder of Emendo Biotherapeutics, where she served as CBO, head of IP and clinical pipeline development.
-
BSc in biotech Engineering from the Technion and an MSc from the Weizmann Institute.
Robert E. Margolin MSc, MBA​
Chief Business Officer ​
-
20 years of experience in biotechnology, with a focus on cell and gene therapy.
-
Former VP of Commercial at Akron Biotech, with additional leadership roles at TrakCel and Cognate BioServices.
-
Brings deep expertise in business development, commercial strategy, and advanced therapeutics.
Ganit Yarden, PhD
Chief Technology Officer​
-
Accomplished biotech executive
-
Held leadership roles at Teva, Merck and Compugen.
-
Ph.D. from the Weizmann Institute in biochemistry.
Board of Directors
Rachel Diamant, MSc Eng.
CEO
-
20 years experience as an entrepreneur in biotech.
-
Co-founder of Emendo Biotherapeutics, where she served as CBO, head of IP and clinical pipeline development.
-
BSc in biotech Engineering from the Technion and an MSc from the Weizmann Institute.
David Baram, PhD
Co-founder and Member of the board
-
25 years of experience as an entrepreneur and a leading CEO
-
Co-founded Emendo Biotherapeutics and as CEO, led the company to a $300M sale.
-
Extensive funding and business experience with over $500M in fundraising
-
Ph.D from the Weizmann Institute under the noble laureate Dr. Ada Yonath.
Peter Kash Ed.D/MBA
Chairman of the Board
-
A biotech entrepreneur, investor, and educator for over 35 years
-
A cofounder/banker of PolaRx, Keryx Biopharmaceuticals, Kite Pharma, Intercept Pharmeucticals, ID Biomedical, TargImmune Therapeutics, iOncologi and others
-
Led to 6 FDA approvals and over $23 billion in peak aggregate market value.
Todd Wider, MD
Member of the Board
-
A surgeon from Columbia University
-
Served as a CMO and Executive Chairman at Emendo Biotherapeutics.
-
Todd has extensive experience as a director in global biotech companies and as an advisor to large biotech investors.
Andrew Haimovici
Member of the Board
-
Investor at TABLE Management LP, Bill Ackman’s investment vehicle.
-
Brings experience investing across private and public companies.
-
Serves as a director of Bremont Watch Company and brings a strong perspective on investment strategy, growth, and value creation.
Our Investors
